Cosentyx (secukinumab) is a biologic medication used to treat various autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. The question of whether Cosentyx is safe for long-term use is an important one for patients who require long-term treatment for their conditions.

According to the drug patent watch [1], the US Food and Drug Administration (FDA) approved Cosentyx for use in 2015. Since then, the medication has undergone several clinical trials to assess its safety and efficacy. The trials have shown that Cosentyx is generally safe for long-term use, with no significant safety concerns reported.

A study published in Arthritis Research & Therapy [2] analyzed the safety and efficacy of Cosentyx in patients with psoriatic arthritis over a period of 52 weeks. The study found that Cosentyx was effective in reducing the symptoms of psoriatic arthritis and was generally well-tolerated by patients. The study did not report any significant safety concerns associated with long-term use of Cosentyx.

Another study published in PubMed [3] assessed the long-term safety and efficacy of Cosentyx in patients with moderate to severe plaque psoriasis. The study followed patients for up to five years and found that Cosentyx was effective in reducing the symptoms of psoriasis and was generally well-tolerated by patients. The study did not report any significant safety concerns associated with long-term use of Cosentyx.

In conclusion, based on the available evidence, Cosentyx appears to be safe for long-term use in patients with autoimmune diseases such as psoriasis, psoriatic arthritis, and ankylosing spondylitis. However, as with any medication, patients should discuss the risks and benefits of long-term treatment with their healthcare provider.

Sources:
[1] https://www.drugpatentwatch.com/p/biologics/tradename/COSENTYX
[2] https://arthritis-research.biomedcentral.com/articles/10.1186/s13075-019-1882-2
[3] https://pubmed.ncbi.nlm.nih.gov/35146532/